Volume 4.04 | Feb 1

Prostate Cell News 4.04 February 1, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Behavioral Stress Accelerates Prostate Cancer Development in Mice
Behavioral stress inhibited apoptosis and delayed prostate tumor involution both in phosphatase and tensin homolog-deficient prostate cancer xenografts treated with PI3K inhibitor and in prostate tumors of mice with prostate-restricted expression of c-MYC subjected to androgen ablation therapy with bicalutamide. [J Clin Invest] Full Article | Press Release

Detect 7 times more prostate epithelial progenitors with ProstaCult
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

β4 Integrin Signaling Induces Expansion of Prostate Tumor Progenitors
Researchers found that a significant fraction of advanced human prostate cancers and castration-resistant metastases express high levels of the β4 integrin, which binds to laminin-5. [J Clin Invest] Full Article

Shrinkage of Experimental Benign Prostatic Hyperplasia and Reduction of Prostatic Cell Volume by a Gastrin-Releasing Peptide Antagonist
Scientists evaluated the effects of gastrin releasing-peptide antagonist RC-3940-II on viability and cell volume of benign prostatic hyperplasia (BPH)-1 human prostate epithelial cells and WPMY-1 prostate stromal cells in vitro, and in testosterone-induced BPH in Wistar rats in vivo. [Proc Natl Acad Sci USA] Abstract

Inhibition of Protein Kinase CK2 Reduces CYP24A1 Expression and Enhances 1,25-Dihydroxyvitamin D3 Anti-Tumor Activity in Human Prostate Cancer Cells
In order to isolate regulators of CYP24A1 expression in prostate cancer cells, the authors established a stable prostate cancer cell line PC3 with the CYP24A1 promoter driving luciferase expression to screen a small molecular library for compounds that inhibit CYP24A1 promoter activity. [Cancer Res] Abstract

Valproic Acid Inhibits the Proliferation of Cancer Cells by Re-Expressing Cyclin D2
Primary murine prostate cancer (PCa) cells were derived using the well-established TRAMP model (transgenic adenocarcinoma mouse prostate). These PCa cells were treated with the histone deacetylase inhibitor, valproic acid (VPA), and researchers demonstrated that VPA treatment has an anti-migrative, anti-invasive and anti-proliferative effect on PCa cells. [Carcinogenesis] Abstract

N-Cadherin Dependent Collective Cell Invasion of Prostate Cancer Cells Is Regulated by the N-Terminus of α-Catenin
Using a cell line from bone metastasis of prostate cancer (PC3), researchers analyzed how prostate cancer cells migrate in a physiologically relevant 3D Matrigel. They found that PC3 cells migrated more efficiently as multi-cellular clusters than isolated single cells, suggesting that the presence of cell-cell adhesion improves 3D cell migration. [PLoS One] Full Article

Expression of Osteoprotegerin from a Replicating Adenovirus Inhibits the Progression of Prostate Cancer Bone Metastases in a Murine Model
Investigators hypothesized that a conditionally replicating adenoviruses armed with osteoprotegerin, an inhibitor of osteoclastogenesis, would inhibit the progression of prostate cancer bone metastases by directly lysing tumor cells and by reducing osteoclast activity. [Lab Invest] Abstract

Apigenin Inhibits TGF-β-Induced VEGF Expression in Human Prostate Carcinoma Cells via a Smad2/3- and Src-Dependent Mechanism
Low oxygen and transforming growth factor-β (TGF-β) are two major factors responsible for increased vascular endothelial growth factor (VEGF) secretion. Experiments were performed to investigate the inhibitory effect of apigenin on TGF-β-induced VEGF production and the mechanisms underlying this action. [Mol Carcinog] Abstract

CLINICAL RESEARCH

Extended vs. Standard Lymph Node Dissection in Robot-Assisted Radical Prostatectomy for Intermediate- or High-Risk Prostate Cancer: A Propensity-Score-Matching Analysis
To overcome the limitation of retrospective analysis, researchers matched preoperative variables using propensity scores and compared the outcomes between patients treated with robot-assisted extended lymph node dissection and standard lymph node dissection. [BJU Int] Abstract

Salvage Radical Prostatectomy as Management of Locally Recurrent Prostate Cancer: Outcomes and Complications
Management of prostate cancer following radiation therapy remains challenging, especially for younger men or those with life expectancy greater than ten years. The authors outline the efficacy, safety and adequacy of radical prostatectomy for the treatment of radiorecurrent localized prostate cancer. [World J Urol] Abstract

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video

REVIEWS
Manipulating the Epigenome for the Treatment of Urological Malignancies
This review discusses DNA methyltransferase and histone deacetylase inhibitors that have been extensively studied in preclinical models and clinical trials for advanced and metastatic urological cancers. [Pharmacol Ther] Abstract
INDUSTRY NEWS

ScinoPharm and Foresee Pharmaceuticals Entered into an Agreement to Establish a Joint Venture for Developing Novel Oncological Peptide Drugs
ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture. This peptide injectable drug is for treatment of prostate cancer and will be the first new drug investment made by ScinoPharm. [ScinoPharm Taiwan., Ltd.] Press Release

WaferGen’s MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
WaferGen Bio-systems, Inc. announced the results of a successful study of lncRNA markers associated with prostate cancer in the lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center. The results can be viewed in white paper form. [WaferGen Bio-systems, Inc.] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW 11th Cancer Immunotherapy (CIMT) Annual Meeting
May 14-16, 2013
Mainz, Germany

Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Androgen Receptor Genomics (The Netherlands Cancer Institute)

Postdoctoral Position – Prostate Cancer Theranostics (The University of Queensland)

PhD Studentship – Genome Mutation Data for the Clinical Management of Patients with Prostate Cancer (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Assistant or Associate Professor – Cancer Biology (Yale School of Medicine)


Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us